Home / Pharmaceuticals / Carcinoembryonic Antigen (CEA) Market, By Application (Ovarian Cancer, Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Breast Cancer, Thyroid Cancer and Other Cancers) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Carcinoembryonic Antigen (CEA) Market, By Application (Ovarian Cancer, Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Breast Cancer, Thyroid Cancer and Other Cancers) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

Published: Sep 2016 | Report Code: 58091-09-16

The report titled “Carcinoembryonic Antigen (CEA) Market- Growth, Future Prospects, and Competitive Analysis, 2016 – 2023” offers strategic insights into the overall carcinoembryonic antigen market along with the market size and estimates for the duration 2013 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of application, and different geographies. CEA is majorly used to measure and observe the protein content in the blood and CAE acts functionally as a tumor marker, especially applied in diagnosis of rectum and colon cancer. The normal level of CEA is expected to be 5 nanograms per milliliter (ng/mL) for adult smokers and less than 2.5ng/ml for adult non-smokers. In addition, a few diseases such as Crohn’s diseases, COPD, and cirrhosis may also result in high CEA levels. Tumor markers for colorectal cancer are used for initial screening of cancer, staging planning & treatment management, and post surgery also in order to understand the incidence rate of cancer. In 2015, colorectal cancer was observed as the largest application market segment due to key market driving factors such as rising demand for minimally invasive cancer diagnosis methods, high influence of sedentary lifestyle in adult population, and increasing public awareness associated with early cancer diagnosis. North America dominated the overall market in terms of revenue share and expected to continue its domination throughout the forecast period due to the rising cancer incidence rates, presence of highly accessible modern healthcare infrastructure, and high patient awareness levels coupled with relatively higher healthcare expenditure levels in the region.

For the purpose of this study, the global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2023, considering 2015 as the base year.

The geographical segmentation of carcinoembryonic antigen (CEA) market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2013 to 2023 and their CAGRs for the period 2016 to 2023 are provided in this report.

The carcinoembryonic antigen (CEA) market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Quest Diagnostics, F. Hoffman LA Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Carcinoembryonic Antigen (CEA) Market, by Application Type, 2015 v/s 2023 (Value %)
2.2 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2015 (Value %)

Chapter 3 Global Carcinoembryonic Antigen (CEA) Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of cancer is boosting the need for research and development in diagnosis methods
3.2.2 Rising demand for minimally invasive cancer diagnosis methods
3.2.3 Growing healthcare expenditure will aid the need for effective diagnostic procedure for cancer in developing countries
3.3 Market Restraints
3.3.1 Early stage cancer diagnosis is still a challenge for CEA method
3.3.2 Regulatory environment in cancer diagnosis is stringent and complicated which hinders the market entry of new companies
3.4 Market Opportunities
3.4.1 Technological enhancement in the cancer diagnosis and especially for early cancer diagnosis
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Carcinoembryonic Antigen (CEA), by Key Players

Chapter 4 Global Carcinoembryonic Antigen (CEA) Market Analysis, By Application Type
4.1 Overview
4.2 Ovarian cancer
4.3 Colorectal Cancer
4.4 Pancreatic Cancer
4.5 Lung Cancer
4.6 Breast Cancer
4.7 Thyroid Cancer
4.8 Other Cancers

Chapter 5 Global Carcinoembryonic Antigen (CEA) Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 Japan
5.4.2 China
5.4.3 Rest of Asia-Pacific
5.5 Latin America
5.5.1 Brazil
5.5.2 Mexico
5.5.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.1.1 Abbott Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 Quest Diagnostics
6.2.1 Quest Diagnostics: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 F. Hoffman LA Roche
6.3.1 F. Hoffman LA Roche: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 GenWay Biotech Inc.
6.4.1 GenWay Biotech Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Correlogic Systems, Inc.
6.5.1 Correlogic Systems, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List of Figures
FIG. 1 Carcinoembryonic Antigen (CEA) Market: Research Methodology
FIG. 2 Global Carcinoembryonic Antigen (CEA) Market, by Application Type, 2015 v/s 2023 (Value %)
FIG. 3 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2015
FIG. 5 Market for Carcinoembryonic Antigen (CEA) Application in Ovarian Cancer, 2013 – 2023 (USD Mn)
FIG. 6 Market for Carcinoembryonic Antigen (CEA) Application in Colorectal Cancer, 2013 – 2023 (USD Mn)
FIG. 7 Market for Carcinoembryonic Antigen (CEA) Application in Pancreatic Cancer, 2013 – 2023 (USD Mn)
FIG. 8 Market for Carcinoembryonic Antigen (CEA) Application in Lung Cancer, 2013 – 2023 (USD Mn)
FIG. 9 Market for Carcinoembryonic Antigen (CEA) Application in Breast Cancer, 2013 – 2023 (USD Mn)
FIG. 10 Market for Carcinoembryonic Antigen (CEA) Application in Thyroid Cancer, 2013 – 2023 (USD Mn)
FIG. 11 Market for Carcinoembryonic Antigen (CEA) Application in Other Cancers, 2013 – 2023 (USD Mn)
FIG. 12 North America Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 13 U.S. Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 14 Canada Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 15 Europe Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 16 U.K. Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 17 Germany Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 18 Rest of Europe Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 19 Asia-Pacific Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 20 Japan Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 21 China Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 22 Rest of Asia-Pacific Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 23 Latin America Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 24 Brazil Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 25 Mexico Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 26 Rest of Latin America Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)
FIG. 27 Middle East and Africa Carcinoembryonic Antigen (CEA) Market , 2013 – 2023 (USD Mn)

List of Tables

TABLE 1 Market Competition Assessment: Carcinoembryonic Antigen (CEA), by Key Players
TABLE 2 Global Carcinoembryonic Antigen (CEA) Market, by Application Type, 2013-2023 (USD Mn)
TABLE 3 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2013 – 2023 (USD Mn)
TABLE 4 Abbott Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 5 Quest Diagnostics: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 F. Hoffman LA Roche: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 GenWay Biotech Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 Correlogic Systems, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

Based on the type of application, the global carcinoembryonic antigen (CEA) market is segmented as follows:

  • Ovarian cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Breast Cancer
  • Thyroid Cancer
  • Other Cancers

In year 2015, colorectal cancer application segment of CEA accounted for the largest share of 41.9% due to the mounting demand for minimally invasive diagnostic procedures, increasing geriatric population base, and increasing sedentary lifestyle in younger population. In addition, high alcohol consumption and lack of physical exercises might also assist the growth of colorectal cancer throughout the forecast period 2016 to 2023. Breast cancer application is anticipated as the fastest growing segment and is expected to grow at a lucrative CAGR of 7.5% by 2023. The key factors that developing the risk of breast cancer are growing number of female population above 50 years, increasing demand for Hormone Replacement Therapy (HRT), and high demand for aesthetic surgeries. However, rising awareness related to breast cancer management among global women population is growing at significant rate which is expected to assist ultimately the growth of CEA market. The market shares of breast cancer application are expected to increase from 16.13% in 2015 to 16.78% in 2023.

 

Carcinoembryonic Antigen (CEA) Market

For the purpose of this study, the global carcinoembryonic antigen (CEA) market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Carcinoembryonic Antigen (CEA) Market

In base year 2015, North America accounted for the largest share in terms of 44.9% due to key drivers such as peaking incidence rates of cancers, existence of sophisticated healthcare infrastructure, high patient awareness levels assisting higher healthcare expenditure levels. In addition, thorough initiatives conducted in the field of research and development organizations functioning in the market include Myraid Genetics, Abbott Laboratories, Qiagen, N.V. Roche Diagnostics, and Life Technologies Corporation providing high quality detection devices across the world. On other hand, Asia-Pacific CEA market is expected to grow at CAGR of 7.2% throughout the forecast period 2016 to 2023. The major factors assisting the exponential growth of this region are availability of untapped opportunities in cancer diagnosis, incessant improvement in healthcare infrastructure, economic development and rising patient awareness levels related to early diagnosis. According to a study published by Pfizer, Among the 15 Asian countries the highest incidence rates (age-standardized) for total cancer (all sites) in males are in Taiwan, Korea, and Japan; female total cancer incidence rates are highest in Taiwan, Singapore, and Philippines. Moreover, supportive government initiatives specific to the eradication, awareness and management of cancer are one of the vital success factors expected to boost the market over the forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients